Tags

Type your tag names separated by a space and hit enter

Amphotericin B lipid preparations: what are the differences?
Clin Microbiol Infect. 2008 May; 14 Suppl 4:25-36.CM

Abstract

To reduce the in-vivo toxicity of the broad-spectrum antifungal drug amphotericin B, various lipid formulations of amphotericin B, ranging from lipid complexes to small unilamellar liposomes, have been developed and subsequently commercialized. These structurally diverse formulations differ in their serum pharmacokinetics as well as their tissue localisation, tissue retention and toxicity. These differences can affect the choice of formulation for a given infection, the time of initiation of treatment, and the dosing regimen. Although preclinical studies have shown similarities in the in-vitro and in-vivo antifungal activity of the formulations with comparable dosing, their acute and chronic toxicity profiles are not the same, and this has a significant impact on their therapeutic indices, especially in high-risk, immunosuppressed patients. With the recent introduction of new antifungal drugs to treat the increasing numbers of infected patients, the amphotericin B lipid formulations are now being studied to evaluate their potential in combination drug regimens. With proven efficacy demonstrated during the past decade, it is expected that amphotericin B lipid formulations will remain an important part of antifungal drug therapy.

Authors+Show Affiliations

Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA. jpadler@csupomona.eduNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

18430127

Citation

Adler-Moore, J P., and R T. Proffitt. "Amphotericin B Lipid Preparations: what Are the Differences?" Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 14 Suppl 4, 2008, pp. 25-36.
Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14 Suppl 4:25-36.
Adler-Moore, J. P., & Proffitt, R. T. (2008). Amphotericin B lipid preparations: what are the differences? Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 14 Suppl 4, 25-36. https://doi.org/10.1111/j.1469-0691.2008.01979.x
Adler-Moore JP, Proffitt RT. Amphotericin B Lipid Preparations: what Are the Differences. Clin Microbiol Infect. 2008;14 Suppl 4:25-36. PubMed PMID: 18430127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amphotericin B lipid preparations: what are the differences? AU - Adler-Moore,J P, AU - Proffitt,R T, PY - 2008/4/24/pubmed PY - 2008/8/15/medline PY - 2008/4/24/entrez SP - 25 EP - 36 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 14 Suppl 4 N2 - To reduce the in-vivo toxicity of the broad-spectrum antifungal drug amphotericin B, various lipid formulations of amphotericin B, ranging from lipid complexes to small unilamellar liposomes, have been developed and subsequently commercialized. These structurally diverse formulations differ in their serum pharmacokinetics as well as their tissue localisation, tissue retention and toxicity. These differences can affect the choice of formulation for a given infection, the time of initiation of treatment, and the dosing regimen. Although preclinical studies have shown similarities in the in-vitro and in-vivo antifungal activity of the formulations with comparable dosing, their acute and chronic toxicity profiles are not the same, and this has a significant impact on their therapeutic indices, especially in high-risk, immunosuppressed patients. With the recent introduction of new antifungal drugs to treat the increasing numbers of infected patients, the amphotericin B lipid formulations are now being studied to evaluate their potential in combination drug regimens. With proven efficacy demonstrated during the past decade, it is expected that amphotericin B lipid formulations will remain an important part of antifungal drug therapy. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/18430127/Amphotericin_B_lipid_preparations:_what_are_the_differences L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(14)61614-1 DB - PRIME DP - Unbound Medicine ER -